Bruno Biscaro has been appointed President of Drug Products, Joe Nettleton as President of Drug Substance, and Simon Edwards as President of CDMO Sales & Marketing
Cambrex Corporation has made three senior appointments to further support the company’s strategy to create the CDMO of choice for small molecules within the pharmaceutical industry.
Bruno Biscaro has been appointed President of Drug Products. In this new role, he will have global responsibility for the company’s drug product business.
Biscaro has over 30 years’ experience in pharmaceutical leadership and joins Cambrex from Famar where he was President, North America. Prior to this role, he was President of Accucaps Industries and has also held numerous leadership positions for GlaxoSmithKline including his last mandate as Regional Director, Global Supply Network Program for the North American Supply Executive Team. He has a master’s degree from the University of Cambridge, UK and a Bachelor of Science degree in Industrial Engineering from Ryerson University in Toronto, Canada.
Joe Nettleton has been appointed as President of Drug Substance with responsibility for operations at the Charles City, Iowa; Karlskoga, Sweden; Wiesbaden, Germany; and Tallinn, Estonia facilities. Nettleton formally held the position of VP of US Operations and has been with Cambrex for 28 years.
Simon Edwards has been appointed as President of CDMO Sales & Marketing. He will provide customers with a single point of contact for the company’s CDMO services, as well as drive commercial activity and brand recognition for Cambrex as the leading small molecule company.
Shawn Cavanagh, EVP and Chief Operating Officer, said: “Our recent acquisitions of Avista and Halo align with this strategy and leverages our core strengths, while positioning us as a leading global provider of end-to-end integrated services for small molecules. These appointments play a crucial role in Cambrex delivering a wider range of services to new and existing customers.”